Navigation Links
VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
Date:1/28/2010

BEDFORD, Mass., Jan. 28 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.  The patent acquisition includes over 45 issued patents worldwide covering a wide range of fluorescence agent constructs and imaging methods, and consolidates VisEn's patent and technology leadership position in the emerging markets of fluorescence imaging from preclinical research through clinical molecular diagnostics.

"We have closely tracked the very high quality of Bayer Schering Pharma's fluorescence agent technologies and extensive patent portfolios over the last decade, and we are pleased to now integrate these platforms into VisEn's programs," said Kirtland Poss, President and CEO of VisEn Medical.  "The acquisition of these assets significantly expands VisEn's patent coverage of in vivo fluorescent imaging agents, and adds to our R&D capability and pipeline of preclinical agent products and clinical imaging agents going forward."

With this acquisition, VisEn's intellectual property portfolio covering fluorescence imaging agents now includes over 150 patents and patent applications worldwide.  The collective patent estate provides comprehensive coverage of a broad range of core agent components and chemistries, as well as key preclinical and clinical applications and methods.  Included in the acquired portfolio are key patents covering physiologic agents, bioconjugates and targeted fluorescence agents, and certain activatable imaging agents for measurement of diverse biomarker activity in living systems.  With the addition of these new platforms, VisEn plans to further expand the aggressive development of its preclinical agent product offerings, as well as its clinical imaging agent pipeline and related programs.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical companies and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical research and clinical program areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

RELATED LINKS
http://www.visenmedical.com

'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
4. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
5. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. U.S. Preventive Medicine Acquires Specialty Disease Management
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
11. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- --> --> Transparency ... titled "Sports Medicine Devices Market - Global Industry Analysis, Size, ... the report, the global sports medicine devices market is anticipated ... growing from a value of US$6.1 bn in 2012 to ... --> The global sports medicine devices market is fueled ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 ... DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel of ... The panel’s goal is to recognize and promote technology entrepreneurship. , The survey ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and ergoFET force gauges used in physical therapy, occupational therapy and sports medicine ... for resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... results in significantly higher rates of several common cancer screenings, especially among women. ... better outcomes and survival rates. , The study,“What Does Medicaid Expansion Mean ...
Breaking Medicine News(10 mins):